Phase 2
Landos Biopharma partnered with Shanghai, China-based LianBio to develop and commercialize omilancor and NX-13 in Greater China and select Asian markets.
A platform trial is also efficient in that it enables the investigators to share placebo information.
Although a quiet week for COVID-19-related clinical trial announcements, there were plenty of others. Read on for more information.
Humanigen reported it had held a meeting with the FDA to discuss plans for filing an EUA for its lenzilumab for hospitalized, hypoxic COVID-19 patients by the end of May.
Biogen reported that its gene therapy, cotoretigene toliparvovec, failed to hit the primary endpoint of the Phase II/III XIRIUS trial for X-linked retinitis pigmentosa (XLRP).
The Rare Disease Company Coalition’s 10 founding members have brought 22 treatments to market and currently have more than 160 rare disease programs in the works.
Pivotal data from Amgen’s and AstraZeneca’s NAVIGATOR Phase III trial show tezepelumab, a potential first-in-class human monoclonal antibody, reduced asthma aggravations and exacerbations requiring hospitalizations better than placebo in patients with severe asthma.
SpliSense, which focuses on cystic fibrosis and other genetic pulmonary diseases, closed on a $28.5 million Series B financing round. The company plans to use the money to advance its pipeline.
Biogen is going all-in on a stroke drug it has been developing for the past three years in collaboration with Japan-based TMS Co.
Please check out the biopharma industry’s COVID-19 stories that are trending for May 11, 2021.
PRESS RELEASES